WhaleCreep

Avidity Partners Management LP 13F holdings, Q3 2022

Hedge fundSEC filingsCompare with another fundHoldings as of 2022-09-30, filed 2022-11-14

Avidity Partners Management LP disclosed 96 US equity positions worth $4.6bn in its Q3 2022 13F filing. Its largest position is LLY at 7.1% of the reported book, followed by UTHR and NBIX. Versus Q2 2022 it opened 29 new positions, added to 26, reduced 19 and exited 15.

$4.6bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
96
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
7.1%
Largest position
The largest single position as a share of the reported equity book.
38.6%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
40
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q2 2022: 29 new, 26 added, 19 reduced, 15 exited

50 of 96
LLY ELI LILLY & COHealthcare7.1%$326m1.01m+65%added
UTHR UNITED THERAPEUTICS CORP DELHealthcare4.4%$203m970,200+34%added
NBIX NEUROCRINE BIOSCIENCES INCHealthcare4.3%$197m1.86m+26%added
ARVN ARVINAS INCHealthcare4.2%$193m4.34m+29%added
ARGX ARGENX SEHealthcare3.8%$174m491,800−14%reduced
BIIB BIOGEN INCHealthcare3.5%$160m600,000+36%added
VRTX VERTEX PHARMACEUTICALS INCHealthcare3.2%$148m512,800−35%reduced
SNDX SYNDAX PHARMACEUTICALS INCHealthcare2.9%$134m5.59m+2.5%added
PRTA PROTHENA CORP PLCHealthcare2.6%$119m1.97m–new
XBI SPDR SERIES TRUST–2.6%$117m1.48m−21%reduced
ACHC ACADIA HEALTHCARE COMPANY INHealthcare2.4%$109m1.39m+34%added
AKROEUR AKERO THERAPEUTICS INC–2.3%$106m3.12m–new
SRPT SAREPTA THERAPEUTICS INCHealthcare2.3%$105m948,200–new
HUM HUMANA INCHealthcare2.2%$103m212,000−49%reduced
BSX BOSTON SCIENTIFIC CORPHealthcare2.1%$98.3m2.54m+0.5%added
IMCR IMMUNOCORE HLDGS PLCHealthcare2.1%$97.6m2.08m+54%added
KRTX KARUNA THERAPEUTICS INC–2.1%$97.1m431,800+111%added
ELV ELEVANCE HEALTH INCHealthcare2.1%$94.3m207,600−53%reduced
HORIZON THERAPEUTICS PUB L no ticker–2.0%$91.7m1.48m−20%reduced
ZNTL ZENTALIS PHARMACEUTICALS INCHealthcare2.0%$91.5m4.22m+18%added
AVTR AVANTOR INCHealthcare1.9%$88.6m4.52m−32%reduced
RARE ULTRAGENYX PHARMACEUTICAL INHealthcare1.8%$85.0m2.05m+39%added
NTRA NATERA INCHealthcare1.7%$76.0m1.74m+27%added
AXSM AXSOME THERAPEUTICS INC.Healthcare1.5%$68.7m1.54m–new
CTLTEUR CATALENT INC–1.5%$68.0m940,000−1.6%reduced
ITCIEUR INTRA-CELLULAR THERAPIES INC–1.4%$65.3m1.40m+81%added
SGENUSD SEAGEN INC–1.3%$61.0m445,500−19%reduced
BIO BIO RAD LABS INCHealthcare1.3%$60.4m144,800–new
ALNY ALNYLAM PHARMACEUTICALS INCHealthcare1.3%$57.7m288,500–new
APLSUSD APELLIS PHARMACEUTICALS INC–1.3%$57.6m844,000+293%added
NTLA INTELLIA THERAPEUTICS INCHealthcare1.2%$55.9m999,100−11%reduced
IDYA IDEAYA BIOSCIENCES INCHealthcare1.2%$55.4m3.72m+25%added
KEZAR LIFE SCIENCES INC no ticker–1.0%$46.6m5.41m+34%added
BLU BELLUS HEALTH INC NEW–1.0%$45.9m4.35m+1.9%added
RVMD REVOLUTION MEDICINES INCHealthcare1.0%$45.8m2.32m+75%added
RNAGBP AVIDITY BIOSCIENCES INC–0.9%$42.5m2.60m+25%added
JAZZ JAZZ PHARMACEUTICALS PLCHealthcare0.9%$42.4m318,300+413%added
ZLAB ZAI LAB LTDHealthcare0.9%$42.2m1.23m–new
ARWR ARROWHEAD PHARMACEUTICALS INHealthcare0.9%$41.5m1.26m−13%reduced
PLRX PLIANT THERAPEUTICS INCHealthcare0.9%$41.4m1.98m–new
DXCM DEXCOM INCHealthcare0.8%$37.7m467,600–new
SYK STRYKER CORPORATIONHealthcare0.8%$37.4m184,700–new
VERVE THERAPEUTICS INC no ticker–0.8%$35.8m1.04m–new
ALT ALTIMMUNE INCHealthcare0.7%$34.3m2.68m−10.0%reduced
CNC CENTENE CORP DELHealthcare0.7%$33.6m432,400–new
CRBU CARIBOU BIOSCIENCES INCHealthcare0.7%$33.5m3.17m+7.5%added
AZN ASTRAZENECA PLCHealthcare0.7%$30.9m563,200−84%reduced
NGMUSD NGM BIOPHARMACEUTICALS INC–0.5%$23.5m1.80m–new
DCPHEUR DECIPHERA PHARMACEUTICALS IN–0.5%$22.0m1.19m−0.7%reduced
POINT BIOPHARMA GLOBAL INC no ticker–0.5%$21.8m2.82m–new

Exited since Q2 2022

15 rows
JNJ JOHNSON & JOHNSON3.7%$160m
MCK MCKESSON CORP2.9%$127m
UNH UNITEDHEALTH GROUP INC2.9%$124m
ABBV ABBVIE INC2.7%$116m
LEGN LEGEND BIOTECH CORP1.3%$55.0m
ARKG ARK ETF TR0.5%$23.6m
VIR VIR BIOTECHNOLOGY INC0.4%$19.3m
NUVB NUVATION BIO INC0.4%$15.7m
XENE XENON PHARMACEUTICALS INC0.3%$13.7m
S SENTINELONE INC0.1%$4.8m
OPHTEUR IVERIC BIO INC0.09%$4.1m
FIELD TRIP HEALTH LTD no ticker0.06%$2.5m
OTICEUR OTONOMY INC0.05%$2.1m
SOCIAL CAP SUVRETTA HLD CRPI no ticker0.05%$2.0m
SOCIAL CAP SUVRETTA HLDS CRP no ticker0.05%$2.0m

Sector mix

  • Healthcare78.2%
  • Unclassified21.8%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters